Abstract
Dear Dr. Martin Hovland, We learned from the literature that premixed insulins are short-acting insulin or rapid-acting insulin analogue mixed with intermediate-acting insulin in a fixed ratio, addressing FBG and PPBG in one injection. There are two categories; high-mix and low-mix premixed insulins. We, a Saudi task force, gathered to develop an explicit, evidence-based consensus for the use of the low-mix premixed insulin for better glycemic control. The treatment with premixed aspart 30 was non-inferior to treatment with premixed insulin lispro 25. In addition, Self-monitored blood glucose levels were comparable. Safety profiles were similar between both treatments, as was the incidence of hypoglycemic episodes. The switch between both products of the low-mix family can be carried out without any problem. Both products of the low-mix premixed insulin analogues aspart 30/70 and premixed insulin lispro 25/75 have comparable efficacy and safety as shown from the medical literature. Therefore, we can change from one to another safely as demonstrated by the US FDA statement. In addition, the ergonomic features of KwikPen’s design and function may offer important advantages for the user during insulin administration.
Highlights
According to the International Diabetes Federation (IDF) Diabetes Atlas, the worldwide prevalence of diabetes mellitus (DM) is expected to become 9.9% by the year 2045 with a total number of 629 Million [1]
The results of this study showed that treatment with premixed aspart 30 was non-inferior to treatment with premixed insulin lispro 25
glide force (GF) was determined for 100 devices (50 of each type); glide force variability (GFV) at 30 and 60 unit doses was calculated for the plateau portion of the force curve based on the minimum and maximum force measured in that portion of the curve [52]
Summary
According to the International Diabetes Federation (IDF) Diabetes Atlas, the worldwide prevalence of diabetes mellitus (DM) is expected to become 9.9% by the year 2045 with a total number of 629 Million [1]. It is associated with significant morbidity and mortality across the globe. Its prevalence is rising rapidly in Saudi Arabia [2] To address both the fasting blood glucose (FBG) and post-prandial blood glucose (PPBG), the premix insulin formulations provide a combination of both rapid/short-acting and intermediate/long-acting insulins in a fixed ratio, in a single injection.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
